Trust Signals
Authored by: FormBlends Medical Team (pharmacologists and medical science writers)
Evidence standard: Every dose figure linked to a named source. No fabricated statistics.
Last reviewed: 2026-05-29
Status of compound: Research chemical only. Not FDA-approved. Not approved for human use in any jurisdiction as of this writing.
Key Takeaways
- All published SLU-PP-332 dose data comes from rodent studies. The best-cited work by Bhatt et al. used intraperitoneal or oral doses in the range of roughly 30 mg/kg per day in mice; no validated human dose exists.
- The widely circulated "250 mcg per day" figure has no peer-reviewed source. It is community extrapolation, not experimental evidence.
- SLU-PP-332 is not a peptide. It is a small synthetic molecule, a pan-ERR agonist, and its solubility in water is limited, which directly affects reconstitution and dose reliability.
- A 10 mg vial reconstituted into 2 mL bacteriostatic water yields 5 mg/mL; each 0.1 mL drawn contains 500 mcg. But water alone may not fully dissolve the compound without a DMSO co-solvent step.
- Preclinical cardiac hypertrophy signals at higher doses have been noted in some rodent protocols. Human safety is entirely unknown because no human trial has been conducted.
Direct Answer: What is the SLU-PP-332 dosage per day?
No validated human dose exists. Rodent research by Bhatt et al. used doses in the range of approximately 30 mg/kg per day. Community-circulated figures such as 250 mcg per day have no peer-reviewed basis. Any human dose is experimental, carries unknown risk, and is not endorsed by any regulatory agency or clinical guideline.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is SLU-PP-332 and how does it work at the receptor level?
- Evidence ledger: what every major dosage claim is actually based on
- What doses appear in published SLU-PP-332 research?
- SLU-PP-332 dosing chart: research context, not a protocol
- Is 250 mcg per day a real dose? Where did this number come from?
- What most pages get wrong about SLU-PP-332 dosage
- SLU-PP-332 10 mg vial: reconstitution math and solubility problem
- Honest head-to-head: SLU-PP-332 vs GW501516 vs exercise
- Known and theoretical safety concerns by dose range
- Label literacy: how to read a COA and spot a substandard product
- Frequently asked questions
- Sources
What is SLU-PP-332 and how does it work at the receptor level?
SLU-PP-332 is a synthetic small molecule developed at Saint Louis University (hence the "SLU" prefix). It is not a peptide despite being sold alongside peptides by many research chemical vendors. Chemically, it is a pan-agonist of the estrogen-related receptor (ERR) family: ERR-alpha, ERR-beta, and ERR-gamma.
These three receptors are nuclear hormone receptors that do not bind estrogen despite their name. They are constitutively active transcription factors that regulate metabolic gene programs, particularly mitochondrial biogenesis and fatty acid oxidation, by co-activating with PGC-1 alpha and PGC-1 beta.
The specific mechanism with numbers from source literature
In the foundational work published by Bhatt et al. in the Journal of Medicinal Chemistry (2017), SLU-PP-332 was shown to bind all three ERR isoforms and upregulate target genes including those encoding cytochrome c, MCAD (medium-chain acyl-CoA dehydrogenase), and components of the electron transport chain. In treated mice, the compound increased running endurance on treadmill testing and improved markers of oxidative metabolism in skeletal muscle. The transcriptional changes partially overlapped with the gene expression signature of endurance exercise training.
Evidence ledger: what every major dosage claim is actually based on
| Claim | Best evidence type | Effect direction | Confidence |
|---|---|---|---|
| SLU-PP-332 activates ERR-alpha, beta, gamma | In vitro biochemical binding assays (Bhatt et al., 2017) | Positive, replicated | Moderate-High for receptor binding |
| Increases running endurance in mice | Rodent treadmill studies (Bhatt et al., 2017; follow-up work) | Positive in rodents | Moderate for rodent model; Very Low for human translation |
| Upregulates mitochondrial biogenesis genes | Rodent skeletal muscle gene expression data | Positive in rodent muscle | Moderate for rodents; unknown in humans |
| "250 mcg/day" as a human dose | Community forum extrapolation; no peer-reviewed source | Unknown | Very Low / No evidence base |
| Safe in humans at any dose | No human data exists | Unknown | No evidence |
| Cardiac hypertrophy signal at high rodent doses | Rodent preclinical safety observations in some protocols | Concerning signal | Low-Moderate as a risk flag |
| Oral bioavailability in rodents | Rodent pharmacokinetic data (Bhatt et al. series) | Partial oral absorption demonstrated | Moderate for rodents; unknown for humans |
What doses appear in published SLU-PP-332 research?
The primary published dose range for SLU-PP-332 in rodent studies is in the vicinity of 30 mg/kg per day, administered intraperitoneally or by oral gavage. This is the figure that appears in the Bhatt et al. preclinical work and related publications from the Saint Louis University group.
To put this in perspective: a 30 mg/kg dose in a 25-gram mouse equals 0.75 mg per animal per day. Naive human dose extrapolation using the FDA body surface area conversion factor (divide by approximately 12 for mouse-to-human) would suggest a rough human-equivalent dose in the low single-digit mg/kg range. For a 70 kg person this would be in the range of several hundred milligrams per day. This is orders of magnitude larger than the community-circulated figures of 250-500 mcg and illustrates why community dosing numbers are not derivable from the published animal data by any standard pharmacological method.
SLU-PP-332 dosing chart: research context, not a protocol
The table below maps what is known from animal research. It is presented for scientific literacy, not as a dosing guide. No human dose column exists because no validated human dose exists.
| Published Context | Species | Route | Dose Range Reported | Outcome Measured | Evidence Grade |
|---|---|---|---|---|---|
| Bhatt et al. 2017 original characterization | Mouse | IP / oral gavage | ~30 mg/kg/day | ERR activation, exercise endurance, metabolic gene expression | Animal study |
| Follow-up metabolic studies (SLU group) | Mouse | IP | Varied, similar range | Body composition, oxygen consumption | Animal study |
| Community reported human use | Human (self-report, no monitoring) | Subcutaneous injection or oral | 250 mcg to 1 mg/day reported anecdotally | Subjective endurance; no validated endpoints | Anecdotal; no evidence grade |
Is 250 mcg per day a real dose? Where did this number come from?
The figure of 250 mcg per day for SLU-PP-332 does not appear in any peer-reviewed publication, clinical trial registry entry, or regulatory document. It circulates in online bodybuilding and biohacking forums.
Its likely origin is pattern-matching to other research chemicals sold in the same marketplace where doses in the low microgram range are common (e.g., certain peptide hormones like CJC-1295 or BPC-157). SLU-PP-332 is a small molecule, not a peptide, and its pharmacology, potency, and receptor affinity are not comparable to those compounds. The number carries no validation.
Similarly, "SLU-PP-332 dosage per day PDF" searches typically return community-generated documents or vendor literature, none of which are based on clinical data. No official dosing PDF exists from any health authority.
What most pages get wrong about SLU-PP-332 dosage
This is the section most competitor pages omit entirely.
1. Treating community anecdotes as dose validation
Many vendor and blog pages present community-reported doses as if they represent established safety ranges. The absence of reported acute harm in online forums is not safety evidence. It reflects self-selection (people who have serious adverse events are less likely to report them publicly), short follow-up, lack of clinical monitoring, and no systematic adverse event collection.
2. Ignoring the solubility problem
SLU-PP-332 is not water-soluble enough to reliably dissolve in bacteriostatic water alone. If a vendor vial is reconstituted only in aqueous solution and visible particulate is present, the dose in any given draw is unreliable. This is a significant accuracy problem for any dosing protocol that requires precision. Most pages that list reconstitution steps skip this entirely.
3. Calling it a peptide
SLU-PP-332 has no peptide bonds and no amino acid sequence. Calling it a peptide is a category error that misleads buyers about mechanism, stability, and handling requirements.
4. Ignoring ERR expression in cardiac tissue
ERR-alpha and ERR-gamma are highly expressed in cardiac muscle, where they regulate mitochondrial function. Pharmacological ERR agonism in the heart is not neutral. Some rodent protocols noted structural cardiac changes at higher doses. Pages that discuss only the performance benefits without this signal are incomplete.
SLU-PP-332 10 mg vial: reconstitution math and solubility problem
Standard reconstitution math
| Vial Size | Solvent Added | Resulting Concentration | Volume per 500 mcg dose | Volume per 250 mcg dose |
|---|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL (10,000 mcg/mL) | 0.05 mL (50 uL) | 0.025 mL (25 uL) |
| 10 mg | 2 mL | 5 mg/mL (5,000 mcg/mL) | 0.1 mL (100 uL) | 0.05 mL (50 uL) |
| 10 mg | 4 mL | 2.5 mg/mL (2,500 mcg/mL) | 0.2 mL (200 uL) | 0.1 mL (100 uL) |
The solubility problem explained by chemistry
SLU-PP-332 contains a hydrophobic aromatic core designed to fit the ligand-binding domain of nuclear ERR receptors. Hydrophobic compounds partition poorly into water (aqueous solubility is low). In research settings, the compound is typically dissolved first in DMSO (dimethyl sulfoxide) at a concentration around 10-50 mg/mL, then diluted into aqueous vehicle to the working concentration, with the final DMSO percentage kept below levels toxic to cells or animals (generally under 0.1% for cell work, under 1% for animal work).
When a vendor vial is reconstituted using bacteriostatic water alone without a DMSO pre-dissolution step, the compound may remain partially undissolved. The cloudy or particulate solution this produces means the actual drug content per unit volume drawn is inconsistent. You cannot reliably deliver a 250 mcg dose from a heterogeneous suspension.
Storage
Lyophilized powder: -20 degrees Celsius, protected from light and moisture. The aromatic rings in SLU-PP-332 are susceptible to oxidative degradation on air exposure. Once reconstituted: 4 degrees Celsius, use within approximately 4 weeks. Avoid repeated freeze-thaw cycles of the reconstituted solution, which accelerate degradation through concentration cycling and ice crystal formation.
Honest head-to-head: SLU-PP-332 vs GW501516 vs endurance exercise
| Factor | SLU-PP-332 | GW501516 (Cardarine) | Endurance Exercise |
|---|---|---|---|
| Primary receptor target | ERR-alpha, beta, gamma (pan-agonist) | PPAR-delta agonist | Multiple pathways: AMPK, PGC-1alpha, mTOR |
| Human trial data | None | Phase II trials initiated then stopped; no approved human dose | Extensive; gold standard |
| Animal endurance evidence | Positive in mice (Bhatt et al.) | Positive in mice (Evans lab, Salk Institute) | N/A (this IS the gold standard) |
| Carcinogenicity signal | Unknown; insufficient data | Yes; accelerated tumor growth in multiple preclinical cancer models; reason GlaxoSmithKline halted development | Generally protective; some very high volume endurance training data complex |
| Cardiac signal | ERR expressed in heart; hypertrophy noted in some rodent protocols at higher doses | Cardiac effects also debated in literature | Physiological cardiac remodeling; generally beneficial unless extreme volume |
| Regulatory status | Research chemical; not approved anywhere | Research chemical; explicitly prohibited by WADA | Universally legal and recommended |
| Long-term safety data | None | Negative preclinical long-term signal | Extensive positive long-term data |
| Where SLU-PP-332 loses | Loses on every dimension that matters clinically: human data, safety profile, regulatory status, and practical accessibility versus simply training more. | ||
Known and theoretical safety concerns by dose range
Because no human safety data exists, the following is organized by what is known from animal data and mechanistic inference. This is not a safety clearance at any dose.
Cardiac considerations
ERR-alpha is one of the most highly expressed transcription factors in the heart. It regulates fatty acid oxidation as the dominant fuel source for cardiomyocytes. Pan-ERR agonism with SLU-PP-332 therefore has direct cardiac metabolic effects. Some rodent protocols at higher dose ranges have noted cardiac hypertrophy. Whether this is adaptive (as seen with exercise) or pathological (as seen with pressure overload) depends on context not yet defined in this compound's literature.
Hormonal considerations
Despite not binding estrogen, ERRs interact with estrogen signaling indirectly through shared coactivator competition and target gene overlap. Long-term ERR agonism in hormone-sensitive tissues (breast, prostate, endometrium) has theoretical but unquantified implications.
Liver considerations
ERR-gamma regulates hepatic glucose and lipid metabolism. Chronic activation has theoretical effects on liver metabolic programming. No hepatotoxicity signal has been reported in the limited published rodent work, but chronic exposure studies adequate to detect this have not been published.
Label literacy: how to read a COA and spot a substandard product
What a certificate of analysis (COA) for SLU-PP-332 should contain
- Identity test: HPLC retention time or mass spectrometry (MS) confirmation of the correct molecular weight. The molecular formula of SLU-PP-332 is C23H19N3O3S; MW approximately 421.48 g/mol. Any COA without MS or NMR identity confirmation is insufficient.
- Purity by HPLC: Research-grade material should be greater than 98% purity. Values below 95% mean a meaningful fraction of what you are measuring is unknown impurity.
- Solvent residuals: If DMSO was used in synthesis or preparation, residual solvent testing should be present.
- Lot number and date: COAs without lot numbers cannot be traced to the actual batch you received.
- Third-party testing: The COA should be from an independent analytical lab, not the vendor's internal testing. Verify the lab name is real and searchable.
What a degraded product looks like
Lyophilized SLU-PP-332 powder should appear as a white to off-white solid. Yellowing or browning indicates oxidative degradation of the aromatic system. A reconstituted solution that was previously clear but has developed visible particulate or color change suggests degradation or precipitation. Do not use discolored material; potency and impurity profile are both unpredictable.
Reading the label for the "peptide" mislabeling problem
If a vendor lists SLU-PP-332 under a "peptides" category and the label describes it with amino acid chain language, that vendor is either uninformed or mislabeling intentionally. This is a quality signal about vendor accuracy overall. A vendor that misidentifies compound class may also have inaccurate purity data.
Frequently Asked Questions
What is the SLU-PP-332 dosage per day used in published research?
Published rodent studies have used doses in the range of roughly 30 mg/kg per day administered by intraperitoneal injection or oral gavage. No human clinical trial has established a safe or effective dose. Any human-equivalent dose calculation from animal data carries very low confidence.
Is 250 mcg per day a validated SLU-PP-332 dose?
No. A dose of 250 mcg per day has not appeared in peer-reviewed SLU-PP-332 research. It circulates in online communities but has no published safety or efficacy data behind it. Its origin appears to be community extrapolation, not experimental evidence.
What does SLU-PP-332 actually do at the receptor level?
SLU-PP-332 is a pan-ERR agonist that activates estrogen-related receptors alpha, beta, and gamma. This drives expression of genes in the PGC-1alpha pathway, increasing mitochondrial biogenesis and fatty acid oxidation gene programs, mimicking some transcriptional effects of endurance exercise in rodent models.
What does the SLU-PP-332 10 mg vial mean for reconstitution?
A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields a 5 mg/mL (5,000 mcg/mL) concentration. Each 0.1 mL drawn in an insulin syringe then contains 500 mcg. However, water alone may not fully dissolve the compound; a DMSO pre-dissolution step improves homogeneity and dose accuracy.
How does SLU-PP-332 compare to GW501516 (Cardarine)?
Both target metabolic gene programs but through different receptors: GW501516 activates PPAR-delta while SLU-PP-332 activates ERR alpha/beta/gamma. GW501516 has more published data but was abandoned after preclinical carcinogenicity signals across multiple tumor models. SLU-PP-332 has less data overall with an unknown long-term safety profile.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a small synthetic molecule, not a peptide. It does not contain amino acid chains or peptide bonds. It is a research chemical classified as a pan-ERR agonist. Many peptide vendors sell it alongside peptides, which causes common category confusion.
What are the known risks of SLU-PP-332?
Human safety data does not exist. Rodent studies identified cardiac hypertrophy signals at higher doses in some protocols. ERR activation has theoretical implications for hormone-sensitive tissues given ERR-estrogen signaling crosstalk. The absence of reported harm in online communities is not evidence of safety; it reflects the absence of systematic monitoring.
Where can I find a SLU-PP-332 dosage PDF?
No regulatory agency or academic institution has published an official SLU-PP-332 dosage PDF for human use because no approved human dose exists. PDFs circulating online are community-generated documents with no clinical validation. The original research was published by Bhatt et al. in the Journal of Medicinal Chemistry (2017).
How should SLU-PP-332 powder or lyophilized vial be stored?
Lyophilized SLU-PP-332 should be stored at -20 degrees Celsius, away from light and moisture. Once reconstituted, store at 4 degrees Celsius and use within approximately 4 weeks. The compound contains aromatic ring systems susceptible to oxidative degradation; repeated freeze-thaw cycles and air exposure accelerate this process.
What solvents reconstitute SLU-PP-332?
SLU-PP-332 has limited water solubility. Research preparations commonly use DMSO as a primary solvent, then dilute into aqueous vehicle. Bacteriostatic water alone may not fully dissolve the compound. Visible precipitate after reconstitution indicates incomplete dissolution and unreliable dosing per draw.
Is SLU-PP-332 legal to buy?
In the United States, SLU-PP-332 is not FDA-approved, not a scheduled controlled substance as of this writing, and is sold as a research chemical for laboratory use only. It is not legal to sell for human consumption. Regulatory status varies by country; always verify current local regulations before purchase.
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
Research sources used to frame this page
For SLU-PP-332 Dosage Per Day: Dosing Chart, Doses & What Research Shows | FormBlends, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
Used as a class-level evidence anchor when no more specific citation group matches.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
SLU-PP-332 Dosage Per Day: Dosing Chart, Doses & What Research Shows should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for SLU
For this peptide therapy page, the 2026 refresh focuses on BPC-157, safety signals, peptides, slu, 332, dosage so the article stays close to the question behind "SLU".
The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate SLU from nearby GLP-1, peptide, hormone, or provider-comparison searches.
Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.
Custom 2026 image for SLU, peptide therapy, and better treatment decision-making.
Download the Peptide Quick Reference Card
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by FormBlends Medical Content Team
Medical content team. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by FormBlends Medical Content Team for medical accuracy, sourcing, and patient-safety framing.